These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Interaction of drugs candidates with various SARS-CoV-2 receptors: an in silico study to combat COVID-19
preprintrevised on 28.04.2020, 13:16 and posted on 29.04.2020, 07:14 by Romulo O. Barros, Fabio L. C. C. Junior, Wildrimak S. Pereira, Neiva M. N. Oliveira, Ricardo Ramos
The world is currently facing the COVID-19 pandemic caused by the SARS-CoV-2 virus. The pandemic is causing the death of people around the world and public and social health measures to slow or prevent the spread of COVID-19 are being implemented with the involvement of all members of society. Research institutions are accelerating the discovery of vaccines and therapies for the COVID-19. In this work, molecular docking was used to study (in silico) the interaction of twenty-four ligands, divided into four groups, with four important SARS-CoV-2 receptors. The results showed that Metaquine (group 01), antimalarial substance and the anti-HIV antiretroviral Saquinavir (group 03), presented interaction with all the studied receptors, indicating that they are potentials candidates for muti-target drugs for COVID-19.
Read the published paper
in Journal of Proteome Research